HOME / Notice / News / EN
Construction site on May 9th Despite the delay in acquiring materials due to COVID-19 crisis, the construction went smoothly according to the plan. NKCL's GMP authorized Automated NK Cell Cultivation Center will not only act as a research and development, but also carry out office works and logistics...
NKCL Bio Group will restart its Global Marketing! Due to COVID-19 pandemic, which has upended economies and wreaked havoc on nearly every country across the globe, NKCL had to temporarily stop its global marketing plans. However, on May 21 (Thu), 2020, NKCL will hold a business seminar in its Shenzhe...
NKCL Bio Group and Labelle Clinic of Gwang-ju, Korea, had signed MOA on April 28th, agreeing upon delivering NK cell treatment. Labelle Clinic has 4 storied building with organized facilities. With director Park Tae-ho, many medical professionals and staff members are working in. Especially, Labelle ...
Despite the delay due to not enough supply of the materials caused by COVID-19 crisis, the construction of ‘NK Cell GMP Automated Cultivation System’ is running smoothly according to the schedule. We share some of the footages of the construction site. NKCL Bio Group’s Automated Cultivation Center...
NKCL Bio Group Inc. (hereinafter referred to as ‘NKCL Bio Group’) is a Korean Bio Group company that researches and develops NK Immune cell treatment which utilizes NK immune cells. With its competitive technologies including cancer cell target treatment and Automatic NK Cell Cultivation System,...